XGEN Venture
Venture Capital and Private Equity Principals
Life Science Venture Capital Investments
About us
XGEN Venture is a venture capital fund manager established in 2021 by the former Genextra team, that specializes in life science investing. We work with a group of exceptional scientists and entrepreneurs to translate high level science into solutions for patients.
- Website
-
www.xgenventure.com
External link for XGEN Venture
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Type
- Privately Held
- Founded
- 2021
Employees at XGEN Venture
-
Michele Manto
Commercial and enterprise build-up, turnaround and scale-up leader | Pharma and Biotech
-
Marija (Masha) Zecevic
Biotechnology Executive
-
Luca Quagliata, PhD, BCMAS, COA
Vice President, Global Head of Medical Affairs at Thermo Fisher Scientific
-
Federica Draghi
Founder & Managing Partner XGEN Venture SGR
Updates
-
We are thrilled to announce our investment in Genespire, a highly innovative Italian in-vivo gene therapy company addressing rare genetic diseases. The oversubscribed Series B financing round secured by a strong syndicate, which includes Sofinnova Partners, CDP Venture Capital SGR and Indaco Venture Partners, will bring the company all the way to clinical trials in a devastating pediatric indication. Special thanks to the Genespire team and to the former CEO, Julia Berretta, who played a key role in this successful achievement. 👉 For more information, visit Genespire website following the link: https://lnkd.in/ggUw4S4q
Today we announced the closing of our €46.6M (~$52M) Series B #financing, co-led by Sofinnova Partners, XGEN Venture and CDP Venture Capital SGR through its Large Venture Fund forming a strong syndicate with Indaco Venture Partners. The financing will enable the development of GENE202, the Company’s lead candidate, up to a Phase I/II clinical trial for the treatment of MMA, a devastating genetic disorder impairing the metabolism of certain amino acids and fats. GENE202, developed by Genespire’s scientific co-founders and gene therapy leaders, Pr. Luigi Naldini and Dr. Alessio Cantore at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), is a pioneering in vivo off-the-shelf gene therapy which harnesses the company’s Immune Shielded Lentiviral Vector (ISLV) platform to address pediatric patients affected by genetic diseases who currently face the most pressing unmet medical needs, while also benefitting adult patients. Special thanks to our previous CEO, Julia Berretta who was instrumental in delivering this successful financing. To read the full press release visit: https://lnkd.in/eQ7Q2dnq #GeneTherapy #BiotechInnovation #LentiViralVectors #Pediatric #Biotech #Innovation #Methylmalonicacidemia #RareDiseases
-
-
🎤Yesterday, May 22, we announced the €160 million raise to the first XGEN's Annual Investor Meeting that took place at STEP FuturAbility District. 🙏A special thank to all participants as well as to the XGEN's team - all of you made it unique. ⏳See you next year! #xgenventure #lifescience #venturecapital #biotech #annualmeeting
-
-
📣We today officially announce that XGEN Venture Life Science Fund has reached a size of €160 million to date, thanks to the support of anchor investors European Investment Fund (EIF), CDP Venture Capital SGR and MICHELI ASSOCIATI SRL, as well as of a broad institutional base including UniCredit, Quaestio Capital SGR S.p.A., BancoBPM, Inarcassa, Fondazione Enpam, Fondazione di Sardegna and Banca Sella Holding. 🌍Our journey through early stage breakthrough life science investments already started with five investments in XGEN's portfolio: PAGE Therapeutics AG, Nouscom , Tes Pharma S.r.l., Protembis GmbH and a soon to be announced gene-therapy company for rare diseases. 🚀Looking forward for all the amazing opportunities to come! #xgenventure #lifescience #venturecapital
XGEN Venture Announces €160 million First Life Science Fund
businesswire.com
-
At xGen Venture, we believe in the transformative potential of cell and gene therapies. These technologies are not just medical breakthroughs; they represent a seismic shift in how we approach the treatment of previously untreatable diseases. We see these advancements as critical investment opportunities that align with our commitment to propelling healthcare forward. Simona Varani, a key member of our investment team, is attending this year's American Society of Gene & Cell Therapy (ASGCT) conference. We are eager to connect with fellow investors and innovative entrepreneurs at the event. If you’re attending, reach out and don’t miss the chance to meet Simona in person to discuss how we can collaborate and support the next wave of biotechnological innovations. See you at ASGCT! #ASGCT #Biotechnology #VentureCapital #GeneTherapy #CellTherapy #Innovation #HealthcareInvestment
-